By Ashleigh Furlong and Jef Feeley | BloombergGSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen. The cases represent about 93% of those against the company involving Zantac, GSK said Wednesday in a statement. The US Food and Drug Administration asked companies producing Zantac to remove all ranitidine-based drugs from the US market in 2020. Pfizer agreed to settle more than 10,000 related cases, Bloomberg reported in May. Valisure had alleged that GSK knew and hid the risks of Zantac from the US government.

Source: Ethiopian News October 10, 2024 00:34 UTC